Clinical Role of Aspirin in Mood Disorders: A Systematic Review

Abstract

Worldwide, depression and bipolar disorder affect a large and growing number of people. However, current pharmacotherapy options remain limited. Despite adequate treatment, many patients continue to have subsyndromal symptoms, which predict relapse in bipolar illness and often result in functional impairments. Aspirin, a common nonsteroidal anti-inflammatory drug (NSAID), has purported beneficial effects on mood symptoms, showing protective effects against depression in early cohort studies. This systematic review thus aimed to investigate the role of aspirin in mood disorders. Using the keywords (aspirin or acetylsalicy* or asa) and (mood or depress* or bipolar or mania or suicid*), a comprehensive search of PubMed, EMBASE, Medline, PsycINFO, Clinical Trials Register of the Cochrane Collaboration Depression, Anxiety and Neurosis Group (CCDANTR), Clinicaltrials.gov and Google Scholar databases found 13,952 papers published in English between 1 January 1988 and 1 May 2019. A total of six clinical studies were reviewed. There were two randomized, placebo-controlled, double-blind trials and populations drawn from two main cohort studies (i.e., the Geelong Osteoporosis Study and the Osteoarthritis Initiative study). Using a random-effects model, the pooled hazard ratio of the three cohort studies was 0.624 (95% confidence interval: 0.0503 to 1.198, p = 0.033), supporting a reduced risk of depression with aspirin exposure. Overall, the dropout rates were low, and aspirin appears to be well-tolerated with minimal risk of affective switch. In terms of methodological quality, most studies had a generally low risk of bias. Low-dose aspirin (80 to 100 mg/day) is safe, well-tolerated and potentially efficacious for improving depressive symptoms in both unipolar and bipolar depression. Due to its ability to modulate neuroinflammation and central nervous system processes, aspirin may also have valuable neuroprotective and pro-cognitive effects that deserve further exploration. Further randomized, controlled trials involving the adjunctive use of aspirin should be encouraged to confirm its therapeutic benefits.

<p>BDNF and the Antidepressant Effects of Ketamine and Propofol in Electroconvulsive Therapy: A Preliminary Study</p>

“…23 Several meta-analyses have found reduced serum levels of BDNF in patients with MDD compared to healthy controls, 24,25 suggesting a role of BDNF as a state-dependent biomarker of MDD. 25 Notably, dissimilar classes of antidepressants 26 or nonsteroidal anti-inflammatory drugs 27 resulted in different regulation of serum BDNF concentrations. Thus, in this study patients with TRD were in a drug-free state during the period of ECT, focusing on the potential correlation between serum levels of BDNF and the antidepressant effects of ECT.…”

<p>The Impact of Childhood Trauma on Developing Bipolar Disorder: Current Understanding and Ensuring Continued Progress</p>

“… 48 Early promising findings of increased low-grade inflammation in adults with BD may be of use for future clinical trials using anti-inflammatory drugs (for example, Minocycline, Acetylsalicylic acid and Celecoxib) as adjunct strategies to treat young people with a first-onset episode; although current recommendations are weak due to a lack of studies in young people. 157 , 168 However, a recent RCT reported that, while inefficient as an adjunct treatment for BD, infliximab, a TNF-α antagonist, reduced the severity of depressive symptoms in individuals with BD exposed to physical or sexual abuse, relative to CT-exposed individuals with BD who used the placebo. 169 Such progress of blood-based markers in addition to known high-risk markers warrants future research studies in young people.…”

<p>The Long-Term Effects of Adolescent Social Defeat Stress on Oligodendrocyte Lineage Cells and Neuroinflammatory Mediators in Mice</p>

“…65 Increasing evidence supports that anti-inflammatory therapeutic adjunct can effectively alleviate depressive symptoms in patients suffering from mood disorders. 66 Collectively, these studies suggest that neuroinflammation may contribute to pathogenesis of stress-related disorders and may serve as a promising therapeutic target for the treatment-resistant mood disorders.…”